We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Genmab Licenses DuoBody Platform to Novo Nordisk

News   Aug 17, 2015

 
Genmab Licenses DuoBody Platform to Novo Nordisk
 
 
Advertisement
 

RELATED ARTICLES

Biologic Therapy for Psoriasis May Also Have Applications in Heart Disease

News

Patients with psoriasis treated with biologic therapy, which are protein-based infusions to suppress inflammation, had a significant reduction in high-risk plaque in heart arteries, over one-year, according to new research.

READ MORE

Tiny Antibody Component Neutralizes SARS-CoV-2 in Animal Models

News

Scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes SARS-CoV-2. This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drug, called Ab8, which holds potential as a therapeutic and prophylactic against SARS-CoV-2.

READ MORE

COVID-19 Phase 3 Trial To Evaluate REGN-COV2 Antibody Cocktail in UK

News

RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world’s largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron’s investigational anti-viral antibody cocktail known as REGN-COV2. The Phase 3 open-label trial in patients hospitalized with COVID-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE